{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"neuronal-ceroid-lipofuscinosis-2","columns":[{"countQualifier":"Onset group unspecified","gene":"TPP1","key":"population-a627e0dd5dda59a802d4","label":"CLN2","mondoId":"MONDO:0008769","onsetQualifier":null,"originColumnKey":"MONDO:0008769","originalViews":[{"key":"MONDO:0008769","label":"CLN2","scopeLabel":"Genetic form","sourceScope":null}],"recordKeys":["118e4ecb55dd4236065a5ad6441400d646958564cb3ba43aeb760e611acffdba","174b7d2a8faba8d425e1c08e3a5a7f47b2184053679ff716a3c20610b8d3edfb","390cc1c9929328869b371097f731a79dd4d5264aa5f2d676ffcbbda0ea83e07e","6a212bc638d2222f5df3fba9bdc63a1846475f884c7da4752b3846846d6b5a24","86e4ece4d56b0438f32adb10a59b5973f2b161d908a57ccd49aea12e055f689a","9cb18c459dca36a1ee70a8019c457c3adad57e54122c6b5d1c50e91a55253672","b37751973220cf08d8c5bd698d5bd252057c3d4a7a11c3d0f5ed8f0d524abb07","b4050709e0939701af20341d5ba0c458ac55a775f753f82f87992b25fee2be37","c594e7cde1c0142a81e1bcac5c9826a429dc4d4f6cd4aa1e39d8c447249cc724","c8b7c78a2c5a2feba297a0c7b520c2df48aa9ed81cfd05a1670302ac1eea0122","d9d858a3303edeb1fa395a8fef57e0b07b01c6d9681539483ba55ee5b72f3e7d","dd443f35032670644f56cd2630ee16e50b5f94132c271684410ecd9520f7d3d7","e78614e8bfe082fa648bb7d4447e413cab922c870687db18b431a5ca8a0a1b78","e862beee2b365d167a09e9cc96b9eb44ce695d4e97a5dcb47135e615df8723b7"],"recordQualifiers":{"86e4ece4d56b0438f32adb10a59b5973f2b161d908a57ccd49aea12e055f689a":"Onset group unspecified"},"scopeLabel":"Genetic form","sourceIds":["OMIM:204500"],"sourceScope":null}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-a627e0dd5dda59a802d4"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0001311","HP:0001251","HP:0002059","HP:0003205","HP:0000750","HP:0002376","HP:0003463"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":1,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":14,"sourceGroups":{"omim":13,"published":1}},"features":[{"hpoId":"HP:0001311","label":"Abnormal nervous system electrophysiology","primary":true},{"hpoId":"HP:0001251","label":"Ataxia","primary":true},{"hpoId":"HP:0002059","label":"Cerebral atrophy","primary":true},{"hpoId":"HP:0003205","label":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","primary":true},{"hpoId":"HP:0000750","label":"Delayed speech and language development","primary":true},{"hpoId":"HP:0002376","label":"Developmental regression","primary":true},{"hpoId":"HP:0003463","label":"Increased extraneuronal autofluorescent lipopigment","primary":true},{"hpoId":"HP:0002074","label":"Increased neuronal autofluorescent lipopigment","primary":false},{"hpoId":"HP:0001336","label":"Myoclonus","primary":false},{"hpoId":"HP:0000529","label":"Progressive visual loss","primary":false},{"hpoId":"HP:6000571","label":"Reduced tissue tripeptidyl peptidase 1 activity","primary":false},{"hpoId":"HP:0000546","label":"Retinal degeneration","primary":false},{"hpoId":"HP:0001250","label":"Seizure","primary":false},{"hpoId":"HP:0000550","label":"Undetectable electroretinogram","primary":false}],"ledeHtml":"CLN2 disease is an inherited disorder that primarily affects the nervous system. The signs and symptoms of this condition typically begin between ages 2 and 4. The initial features usually include recurrent seizures (epilepsy) and difficulty coordinating movements (ataxia). Affected children also develop muscle twitches (myoclonus) and vision loss. CLN2 disease affects motor skills, such as sitting and walking, and speech development. This condition also causes the loss of previously acquired skills (developmental regression), intellectual disability that gradually gets worse, and behavioral problems. Individuals with this condition often require the use of a wheelchair by late childhood and typically do not survive past their teens.","mondoId":"MONDO:0008769","node":{"canonicalSlug":"neuronal-ceroid-lipofuscinosis-2","comparisons":[{"documentSha256":"feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069","key":"legacy-cln","kind":"legacy","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/cln.feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069.json"},{"documentSha256":"df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3","key":"expanded-cln","kind":"expanded","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012188","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295","MONDO:0017809","MONDO:0019260","MONDO:0019261","MONDO:0019262","MONDO:0030947","MONDO:0850001"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-df7e5010cb40de30aba1.df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":["Mutations in the TPP1 gene cause CLN2 disease. The TPP1 gene provides instructions for producing an enzyme called tripeptidyl peptidase 1. This enzyme is found in cell structures called lysosomes, which digest and recycle different types of molecules. Tripeptidyl peptidase 1 breaks down protein fragments, known as peptides, into their individual building blocks (amino acids).","Mutations in the TPP1 gene greatly reduce or eliminate the production or activity of the tripeptidyl peptidase 1 enzyme. A reduction in functional enzyme results in the incomplete breakdown of certain peptides. CLN2 disease, like other NCLs, is characterized by the accumulation of proteins or peptides and other substances in lysosomes. These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects. The accumulations can cause cell damage leading to cell death. The progressive death of nerve cells in the brain and other tissues leads to the signs and symptoms of CLN2 disease.","Individuals who are diagnosed with CLN2 disease later in childhood likely have TPP1 gene mutations that result in the production of an enzyme with a small amount of normal function. Protein function in these individuals is higher than in those who have the condition beginning earlier in childhood. As a result, it takes longer for peptides and other substances to accumulate in the lysosomes and damage nerve cells."],"causesUrl":"https://medlineplus.gov/genetics/condition/cln2-disease/#causes","contentForm":"summary","matchMethod":"reviewed-binding","name":"CLN2 disease","paragraphs":["CLN2 disease is an inherited disorder that primarily affects the nervous system. The signs and symptoms of this condition typically begin between ages 2 and 4. The initial features usually include recurrent seizures (epilepsy) and difficulty coordinating movements (ataxia). Affected children also develop muscle twitches (myoclonus) and vision loss. CLN2 disease affects motor skills, such as sitting and walking, and speech development. This condition also causes the loss of previously acquired skills (developmental regression), intellectual disability that gradually gets worse, and behavioral problems. Individuals with this condition often require the use of a wheelchair by late childhood and typically do not survive past their teens.","Some children with CLN2 disease do not develop symptoms until later in childhood, typically after age 4. These individuals tend to have milder features overall compared to those diagnosed earlier, but with more severe ataxia. They have a shortened life expectancy, although they tend to survive into adulthood.","CLN2 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation \"CLN,\" meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype."],"reviewed":"2016-11","scope":"exact","scopeNote":"","source":"MedlinePlus","sourceRelease":"2026-10-01","upstream":"MedlinePlus Genetics","url":"https://medlineplus.gov/genetics/condition/cln2-disease"},"ownColumnKeys":["population-a627e0dd5dda59a802d4"],"publication":"published","relationships":[{"kind":"parent","label":"neuronal ceroid lipofuscinosis","mondoId":"MONDO:0016295","slug":"cln"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"native-cross-reference-does-not-establish-scope","source":"MedlinePlus","url":"https://medlineplus.gov/genetics/condition/cln2-disease"}],"translation":"pending","articles":[{"articleId":"rarediseases.info.nih.gov/diseases/3045","pageMondoId":"MONDO:0008769","source":"GARD","name":"Neuronal ceroid lipofuscinosis 2","url":"https://rarediseases.info.nih.gov/diseases/3045","relationToPage":"same-condition","coveredMondoIds":["MONDO:0008769"],"status":"validated-exact-source","presentation":"additional-reference","evidence":["existing-offline-scope-validator","automatic-identity-and-attribution"],"reviewed":null,"sourceRelease":"2026-10-25T03:38:54Z","upstream":"GARD:0003045","rawAttribution":"MONDO:0008769","independentCorroborationEstablished":false}]},"records":[{"frequencyKind":"reported","key":"118e4ecb55dd4236065a5ad6441400d646958564cb3ba43aeb760e611acffdba","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001250","is_excluded":false,"label":"Seizure","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"174b7d2a8faba8d425e1c08e3a5a7f47b2184053679ff716a3c20610b8d3edfb","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002074","is_excluded":false,"label":"Increased neuronal autofluorescent lipopigment","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"390cc1c9929328869b371097f731a79dd4d5264aa5f2d676ffcbbda0ea83e07e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002059","is_excluded":false,"label":"Cerebral atrophy","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"6a212bc638d2222f5df3fba9bdc63a1846475f884c7da4752b3846846d6b5a24","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000529","is_excluded":false,"label":"Progressive visual loss","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"86e4ece4d56b0438f32adb10a59b5973f2b161d908a57ccd49aea12e055f689a","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"PCS","frequency_raw":"2/2","hpo_id":"HP:6000571","is_excluded":false,"label":"Reduced tissue tripeptidyl peptidase 1 activity","onset_id":null,"reference":"PMID:37922835","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"9cb18c459dca36a1ee70a8019c457c3adad57e54122c6b5d1c50e91a55253672","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000550","is_excluded":false,"label":"Undetectable electroretinogram","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"b37751973220cf08d8c5bd698d5bd252057c3d4a7a11c3d0f5ed8f0d524abb07","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001251","is_excluded":false,"label":"Ataxia","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"b4050709e0939701af20341d5ba0c458ac55a775f753f82f87992b25fee2be37","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000546","is_excluded":false,"label":"Retinal degeneration","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"c594e7cde1c0142a81e1bcac5c9826a429dc4d4f6cd4aa1e39d8c447249cc724","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000750","is_excluded":false,"label":"Delayed speech and language development","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"c8b7c78a2c5a2feba297a0c7b520c2df48aa9ed81cfd05a1670302ac1eea0122","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003205","is_excluded":false,"label":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"d9d858a3303edeb1fa395a8fef57e0b07b01c6d9681539483ba55ee5b72f3e7d","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001336","is_excluded":false,"label":"Myoclonus","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"dd443f35032670644f56cd2630ee16e50b5f94132c271684410ecd9520f7d3d7","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002376","is_excluded":false,"label":"Developmental regression","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"e78614e8bfe082fa648bb7d4447e413cab922c870687db18b431a5ca8a0a1b78","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003463","is_excluded":false,"label":"Increased extraneuronal autofluorescent lipopigment","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"e862beee2b365d167a09e9cc96b9eb44ce695d4e97a5dcb47135e615df8723b7","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204500","disease_name":"Ceroid lipofuscinosis, neuronal, 2","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001311","is_excluded":false,"label":"Abnormal nervous system electrophysiology","onset_id":null,"reference":"OMIM:204500","source_release":"2026-06-23"},"sourceGroups":["omim"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln2-disease\" rel=\"noreferrer\">MedlinePlus</a></p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/3045\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0008769\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>reviewed-binding</dd><dt>Upstream attribution</dt><dd>MedlinePlus Genetics</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>CLN2 disease is an inherited disorder that primarily affects the nervous system. The signs and symptoms of this condition typically begin between ages 2 and 4. The initial features usually include recurrent seizures (epilepsy) and difficulty coordinating movements (ataxia). Affected children also develop muscle twitches (myoclonus) and vision loss. CLN2 disease affects motor skills, such as sitting and walking, and speech development. This condition also causes the loss of previously acquired skills (developmental regression), intellectual disability that gradually gets worse, and behavioral problems. Individuals with this condition often require the use of a wheelchair by late childhood and typically do not survive past their teens.</p><p>Some children with CLN2 disease do not develop symptoms until later in childhood, typically after age 4. These individuals tend to have milder features overall compared to those diagnosed earlier, but with more severe ataxia. They have a shortened life expectancy, although they tend to survive into adulthood.</p><p>CLN2 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation &quot;CLN,&quot; meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln2-disease\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"overview","title":"Overview"},{"bodyHtml":"<p>Mutations in the TPP1 gene cause CLN2 disease. The TPP1 gene provides instructions for producing an enzyme called tripeptidyl peptidase 1. This enzyme is found in cell structures called lysosomes, which digest and recycle different types of molecules. Tripeptidyl peptidase 1 breaks down protein fragments, known as peptides, into their individual building blocks (amino acids).</p><p>Mutations in the TPP1 gene greatly reduce or eliminate the production or activity of the tripeptidyl peptidase 1 enzyme. A reduction in functional enzyme results in the incomplete breakdown of certain peptides. CLN2 disease, like other NCLs, is characterized by the accumulation of proteins or peptides and other substances in lysosomes. These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects. The accumulations can cause cell damage leading to cell death. The progressive death of nerve cells in the brain and other tissues leads to the signs and symptoms of CLN2 disease.</p><p>Individuals who are diagnosed with CLN2 disease later in childhood likely have TPP1 gene mutations that result in the production of an enzyme with a small amount of normal function. Protein function in these individuals is higher than in those who have the condition beginning earlier in childhood. As a result, it takes longer for peptides and other substances to accumulate in the lysosomes and damage nerve cells.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln2-disease/#causes\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"causes","title":"Causes"}],"sharedSources":[],"slug":"neuronal-ceroid-lipofuscinosis-2","sourceDocuments":[{"name":"MedlinePlus: CLN2 disease","reviewed":"2016-11","source_release":"2026-10-01","url":"https://medlineplus.gov/genetics/condition/cln2-disease"},{"name":"GARD: Neuronal ceroid lipofuscinosis 2","reviewed":null,"source_release":"2026-10-25T03:38:54Z","url":"https://rarediseases.info.nih.gov/diseases/3045"},{"name":"MONDO: neuronal ceroid lipofuscinosis 2","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0008769"}],"sourceNote":"","synonyms":["ceroid lipofuscinosis, neuronal, 2","ceroid lipofuscinosis, neuronal, type 2","CLN2","CLN2 disease, juvenile (subtype)","CLN2 disease, late infantile (subtype)","neuronal ceroid lipofuscinosis caused by mutation in TPP1","neuronal ceroid lipofuscinosis type 2","TPP1 neuronal ceroid lipofuscinosis"],"takeawayHtml":"","title":"neuronal ceroid lipofuscinosis 2"},"schemaVersion":1}
